

Lemon Tree Hotels

India | Hotels | Result Update



10 February 2026

In-line operational performance

Lemon Tree Hotels (LEMONTREE IN) reported in-line operational performance, driven by 9.5% growth in RevPAR and 10% growth in consolidated management fees. Asset addition pipeline continues to swell for LEMONTRE, driven by managed hotels (up by 1,855 keys in Q3 to 9,364 keys), but new hotel openings have been sluggish, in our view. Growth in the next two years will be driven by mix improvement at Aurika Mumbai, opening of the 91-key Aurika at Shimla in FY27, higher management fee income and double-digit RevPAR growth for owned portfolio. LEMONTRE is the best stock to play on growth in the mid-market hotel segment but partial gains on profitability due to the industry upcycle are being eroded by recurring renovation expenses. **Maintain Accumulate with SoTP-TP of INR 157.**

Front-loaded investments, GST changes weigh on margins: EBITDA margin declined 145bps to 50.4% in Q3FY26, primarily on account of higher investments towards renovations, technology upgrades and the GST impact. Collectively, these cost heads accounted for 6.4% of revenue in Q3FY26. Management indicated that these investments are front-loaded in nature and are expected to normalize to 3.6% of revenue by FY28, which should drive expansion in EBITDA margin. GST impact accounted for 1.8% of revenue in Q3 and is expected to remain around similar levels in FY28.

Targeted rebranding to enhance rate potential: Management is pursuing selective rebranding alongside renovations, targeting assets with clear pricing upside, driven by location and product repositioning. The rebranding of *Red Fox Hotel, New Delhi* to Lemon Tree Hotel has already delivered a meaningful improvement in ARR, though this impact is not fully reflected in RevPAR. Similar initiatives are underway, including the planned rebranding of *Red Fox Hyderabad* to Lemon Tree Hotel by October CY26 and the conversion of select *Keys* assets, such as *Keys Whitefield* to *Keys Prima* following the completion of renovation in the next 6-8 months. Separately, Lemon Tree Alleppey, is being evaluated for a potential upgrade to the *Aurika* brand in the longer term, while *Red Fox Jaipur* (180-key) is being assessed for redevelopment into an *Aurika*-format hotel, supported by the high underlying land value.

Aurika-led development pipeline: Capex continues to be directed towards the development of the Aurika portfolio. As of 31 December 2025, capital deployed at 91-key Aurika, Shimla stood at INR 0.66bn, with the property expected to commence operations in FY27. Aurika, Shillong (165 keys) has seen a cumulative capex of INR 0.15bn out of total INR 2bn and is slated for opening in Q3FY28. Capex for *Aurika, Nehru Place, New Delhi* (~550 keys) is yet to be announced and will be finalised post receipt of requisite approvals.

Maintain Accumulate with TP retained at INR 157: We keep our estimates unchanged. We have not factored in the impact of LEMONTRE's restructuring in our financials due to inadequate financial data. Maintain Accumulate with SoTP-TP of INR 157.

Rating: **Accumulate**

Target Price: **INR 157**

Upside/Downside: **18%**

CMP: **INR 133**

As on 10 February 2026

Key data

Bloomberg	LEMONTRE IN
Reuters Code	LEMO.NS
Shares outstanding (mn)	792
Market cap (INR bn/USD mn)	105/1,162
EV (INR bn/USD mn)	131/1,446
ADTV 3M (INR mn/USD mn)	503/6
52 week high/low	181/111
Free float (%)	63

Note: as on 10 February 2026; Source: Bloomberg

Price chart



Source: Bloomberg

Shareholding (%)	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Promoter	22.5	22.3	22.3	22.3
% Pledge	0.0	0.0	0.0	0.0
FII	36.0	21.3	21.5	21.5
DII	19.7	20.0	19.7	19.5
Others	21.8	36.4	36.5	36.7

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	1.4	6.5	10.9
Lemon Tree Hotels	(17.6)	(7.3)	(2.7)
NSE Mid-cap	1.1	6.9	13.2
NSE Small-cap	(3.9)	(1.2)	4.2

Source: Bloomberg

Key Financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	10,711	12,861	14,256	16,066	17,606
YoY (%)	16.9	21.2	8.2	18.0	13.7
EBITDA (INR mn)	5,232	6,341	6,862	8,095	9,208
EBITDA margin (%)	48.8	49.3	48.1	50.4	52.3
Adj PAT (INR mn)	1,485	1,968	2,322	3,212	4,010
YoY (%)	-	-	-	-	-
Fully DEPS (INR)	1.9	2.5	2.9	4.1	5.1
RoE (%)	10.0	11.8	11.8	13.4	13.7
RoCE (%)	12.5	14.3	15.4	17.7	18.9
P/E (x)	70.8	53.5	45.3	32.7	26.2
EV/EBITDA (x)	25.0	20.7	19.1	16.2	14.2

Note: Pricing as on 10 February 2026; Source: Company, Elara Securities Estimate

Prashant Biyani

Fertilizers & Agricultural Chemicals,
Hotels, Sugar
+91 22 6164 8581
prashant.biyani@elaracapital.com

Associates
Yashi Jain
yashi.jain@elaracapital.com



Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	10,711	12,861	14,256	16,066	17,606
Gross Profit	10,083	12,099	13,404	15,087	16,524
EBITDA	5,232	6,341	6,862	8,095	9,208
EBIT	4,111	4,948	5,443	6,622	7,680
Interest expense	2,085	2,112	1,807	1,545	1,315
Other income	125	129	139	150	163
Exceptional/ Extra-ordinary items	-	-	-	-	-
PBT	2,151	2,965	3,776	5,227	6,528
Tax	341	529	954	1,320	1,648
Minority interest/Associates income	(325)	(468)	(500)	(695)	(870)
Reported PAT	1,485	1,968	2,322	3,212	4,010
Adjusted PAT	1,485	1,968	2,322	3,212	4,010
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	9,669	11,635	14,801	18,724	23,776
Minority Interest	5,795	6,261	6,771	7,476	8,356
Trade Payables	859	616	781	880	965
Provisions & Other Current Liabilities	608	773	855	958	1,045
Total Borrowings	18,891	16,986	14,434	12,434	10,434
Other long term liabilities	4,508	4,546	4,669	4,718	4,762
Total liabilities & equity	40,330	40,818	42,312	45,190	49,338
Net Fixed Assets	35,298	34,731	35,408	35,934	36,207
Goodwill	951	951	951	951	951
Intangible assets	400	449	165	165	165
Business Investments / other NC assets	1,628	1,753	3,025	3,815	4,515
Cash, Bank Balances & treasury investments	618	1,192	788	2,104	4,658
Inventories	138	138	195	220	241
Sundry Debtors	715	786	898	1,012	1,109
Other Current Assets	582	817	881	989	1,492
Total Assets	40,330	40,818	42,312	45,190	49,338
Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Cashflow from Operations	4,650	5,416	5,852	6,710	7,506
Capital expenditure	(3,305)	(932)	(2,046)	(2,000)	(1,800)
Acquisitions / divestitures	-	(58)	-	-	-
Other Business cashflow	(660)	(285)	139	150	163
Free Cash Flow	685	4,141	3,945	4,860	5,869
Cashflow from Financing	(351)	(3,567)	(4,349)	(3,545)	(3,315)
Net Change in Cash / treasury investments	334	574	(404)	1,315	2,554
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	-	-	-	-	-
Book value per share (INR)	12.2	14.7	18.7	23.7	30.0
RoCE (Pre-tax) (%)	12.5	14.3	15.4	17.7	18.9
ROIC (Pre-tax) (%)	12.6	14.7	15.8	18.5	20.6
ROE (%)	10.0	11.8	11.8	13.4	13.7
Asset Turnover (x)	0.3	0.4	0.4	0.5	0.5
Net Debt to Equity (x)	1.9	1.4	0.9	0.6	0.2
Net Debt to EBITDA (x)	3.5	2.5	2.0	1.3	0.6
Interest cover (x) (EBITDA/ int exp)	2.5	3.0	3.8	5.2	7.0
Total Working capital days (WC/rev)	22.0	47.9	30.3	59.9	119.0
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	70.8	53.5	45.3	32.7	26.2
P/Sales (x)	9.8	8.2	7.4	6.6	6.0
EV/ EBITDA (x)	25.0	20.7	19.1	16.2	14.2
EV/ OCF (x)	28.2	24.2	22.4	19.5	17.4
FCF Yield	0.5	3.2	3.0	3.7	4.5
Price to BV (x)	10.9	9.0	7.1	5.6	4.4
Dividend yield (%)	-	-	-	-	-

Note: Pricing as on 10 February 2026; Source: Company, Elara Securities Estimate

Exhibit 1: Quarterly Financials

Consolidated financials (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Variance (%)	9MFY26	9MFY25	YoY (%)
Cons net sales	4,061	3,552	14.3	3,063	32.6	3,153	28.8	10,281	9,076	13.3
Raw material	230	196	17.2	200	14.9	195	17.8	629	532	18.1
% of Net Sales	5.7	5.5	14bp	6.5	-87.4	6.2	-53bp	6.1	5.9	25bp
Employee Cost	594	564	5.3	585	1.5	504	17.8	1,759	1,614	9.0
Other Expenses	985	734	34.1	744	32.3	781	26.2	2,485	1,953	27.3
Power & Fuel	205	215	(4.7)	226	(9.3)	189	8.2	649	676	(4.0)
Total Expenditure	2,014	1,710	17.8	1,756	14.7	1,670	20.6	5,522	4,776	15.6
EBITDA	2,047	1,842	11.1	1,307	56.6	1,483	38.0	4,759	4,300	10.7
Margin (%)	50.4	51.9	-145bp	42.7	773bp	47.0	337bp	46.3	47.4	-109bp
Depreciation	348	351	(0.8)	343	1.4	355	(2.0)	1,033	1,044	(1.1)
EBIT	1,699	1,491	13.9	964	76.2	1,128	50.6	3,726	3,256	14.4
Interest	444	526	(15.6)	451	(1.4)	500	(11.2)	1,374	1,606	(14.4)
Other Income	47	29	60.0	45	4.6	40	16.9	141	87	62.5
Exceptional Items	(313)	-	NA	-	NA	-	NA	(313)	-	NA
PBT	988	994	(0.6)	558	77.0	668	47.9	2,179	1,736	25.5
Tax	170	197	(13.4)	139	22.5	167	1.7	457	390	17.2
Tax Rate (%)	17.2	19.8	-256bp	24.9	-767bp	25.0	-782bp	21.0	22.4	-149bp
RPAT	627	625	0.3	346	81.3	502	24.9	1,356	1,119	21.1
APAT	940	625	50.4	346	172.0	386	143.2	1,669	1,119	49.1
Adj EPS (INR)	1.19	0.79	50bp	0.4	172bp	0.49	143bp	2.1	1.4	49bp

Source: Company, Elara Securities Estimate

Healthy pipeline additions; premium brand expansion: In Q3FY26, LEMONTRE signed 17 new management and franchise contracts, adding 1,855 rooms to its pipeline, underscoring sustained momentum in its asset-light expansion strategy. It continues to strengthen its premium *Aurika* brand, which currently comprises seven hotels (four managed and three owned/PPP). Management plans to operationalize two of the three blocks at the 91-key Aurika, Shimla by Q2FY27, enabling the property to capture peak summer demand. Additionally, effective 1 October 2025, *Red Fox Hotel – Aerocity*, New Delhi was rebranded as Lemon Tree Hotel – Aerocity, New Delhi, in line with the group's strategy of brand consolidation and portfolio upgradation.

Management fees grew at 10% YoY: Management fee grew by 10% YoY to INR 482mn (from an elevated base of INR 437mn), driven by a 25% YoY growth in fees from third parties to INR 229mn. Management fees from Fleur Hotels to LEMONTRE was flat at INR 253mn, impacted by GST changes and accelerated renovation in the portfolio. Enterprise revenue grew by 16% YoY to INR 6.4bn, driven by 10% growth in owned and 24% growth in managed portfolios.

Corporate restructuring to streamline platform focus: Recently, LEMONTRE announced a composite reorganization to separate its asset-light hotel management and fee-based platform (Lemon Tree Hotels) from the asset-heavy ownership platform (Fleur Hotels). As part of the transaction, Warburg Pincus has acquired APG's entire 41% stake in Fleur and committed up to INR 9.6bn of primary equity to support Fleur's growth, with Fleur expected to be listed over the next 12-15 months.

Post-implementation, LTH will operate as a pure-play, debt-free, asset-light hotel management and brand platform, retaining its brand, management, loyalty program and distribution. The fee-based model will deliver ~70%+ EBITDA margin, with third-party pipeline exceeding ~9,400 rooms, positioning LTH as a high-growth, high-RoCE platform.

Exhibit 2: Valuation

Particulars (INR mn)	FY26E	FY27E	FY28E
Topline from owned hotels in standalone entity	580	609	639
Management fees from 3rd party (A)	803	1,083	1,279
Management fees from Fleur (B)	1,177	1,236	1,319
Total management fees (C= A+B)	1,980	2,318	2,597
Implied EBITDA From Owned hotels	319	335	352
Implied EBITDA from Managed hotels	1,584	1,855	2,078
Implied PAT from owned hotels	128	134	141
Implied PAT from management fee business	1,188	1,391	1,558
Indicative M. Cap from Owned Hotels (D)	3,827	4,018	4,219
Indicative M. Cap from management fee business (E)	59,403	69,547	77,924
Fleur Hotels EBITDA	5,440	5,801	6,330
Fleur Hotels EV @ 18x multiple (F)	97,917	104,420	113,942
Fleur Hotels Debt (G)	16,000	16,000	16,000
Indicative M. Cap of Fleur Hotels (H=I-J)	81,917	88,420	97,942
Direct Value of LEMONTRE in Fleur @41.03%	33,611	36,279	40,186
Value after adjusting 20% holding company discount on above (K)	26,889	29,023	32,149
Indirect Value of LEMONTRE in Fleur @25.62% (L)	8,611	9,295	10,296
SoTP of LEMONTREE (D+E+K+L)	98,729	111,883	124,587
O/S Shares of LEMONTREE	791.6	791.6	791.6
Target price			157

Source: Elara Securities Estimate

Exhibit 3: Nine managed hotels (816 keys) operationalized in Q3FY26

Portfolio break-down operational (no.)	Owned	Leased	Managed/franchised	Total
Aurika				
Rooms	808	-	-	808
Hotels	2	-	-	2
Lemon Tree Premier				
Rooms	1,442	161	1,364	2,967
Hotels	7	2	14	23
Lemon Tree				
Rooms	1,448	321	3,437	5,206
Hotels	14	4	55	73
Red Fox				
Rooms	552	91	360	1,003
Hotels	4	1	4	9
Keys Prima				
Rooms	-	-	130	130
Hotels	-	-	3	3
Keys Select				
Rooms	936	-	354	1,290
Hotels	7	-	5	12
Keys Lite				
Rooms	-	-	368	368
Hotels	-	-	8	8
Total				
Rooms	5,186	573	6,013	11,772
Hotels	34	7	89	130

Source: Company, Elara Securities Research

Exhibit 4: Nine hotels (906 keys) of Lemon Tree brand signed in Q3FY26

Portfolio break-down pipeline (no.)	Owned	Leased	Public-private partnership	Managed/franchised	Total
Aurika					
Rooms	641	0	165	499	1305
Hotels	2	0	1	4	7
Lemon Tree Premier					
Rooms	0	0	0	1,136	1136
Hotels	0	0	0	11	11
Lemon Tree					
Rooms	0	0	0	5,481	5481
Hotels	0	0	0	69	69
Red Fox					
Rooms	0	0	0	50	50
Hotels	0	0	0	1	1
Keys Prima					
Rooms	0	0	0	435	435
Hotels	0	0	0	6	6
Keys Select					
Rooms	0	0	0	1,230	1230
Hotels	0	0	0	22	22
Keys Lite					
Rooms	0	0	0	533	533
Hotels	0	0	0	13	13
Total					
Rooms	641	0	165	9364	10170
Hotels	2	0	1	126	129

Source: Company, Elara Securities Research

Exhibit 5: Occupancy down 80bps YoY in Q3FY26

	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
ARR (INR)	6,333	6,605	5,686	5,902	6,763	7,042	6,236	6,247	7,487
% YoY	10.4	13.4	8.6	12.0	6.8	6.6	9.7	5.8	10.7
Occupancy (%)	66	72	67	68	74	78	73	70	73
Increase/ (Decrease) in bps	-170.0	-160.0	-360.0	-330.0	830.0	560.0	590.0	140.0	-80.0
RevPAR (INR)	4,176	4,756	3,788	4,035	5,018	5,462	4,523	4,358	5,494
% YoY	7.7	10.9	3.0	6.9	20.2	14.9	19.4	8.0	9.5

Source: Company, Elara Securities Research

Exhibit 6: Total room count at 21,942

Room count (no.)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Owned/leased rooms	5,759	5,759	5,759	5,759	5,759	5,759	5,759	5,759	5,759
Managed/ franchised rooms	3,928	4,104	4,366	4,559	4,558	4,510	4,902	5,197	6,013
Total operational rooms	9,687	9,863	10,125	10,318	10,317	10,269	10,661	10,956	11,772
Pipeline rooms	3,746	4,156	3,967	5,220	5,879	6,847	7,770	9,118	10,170
Total operational + pipeline rooms	13,433	14,019	14,092	15,538	16,196	17,116	18,431	20,074	21,942

Source: Company, Elara Securities Research

Exhibit 7: Management fee from Fleur flat and from third party grew 24% YoY in Q3

	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Total management fees (INR mn)	323	383	291	318	437	444	374	343	482
From third party to Lemon Tree	149	144	125	134	184	160	161	143	229
From Fleur to Lemon Tree	174	239	166	184	253	283	213	199	253

Source: Company, Elara Securities Research

Exhibit 8: Enterprise revenue from managed hotels grew 24% YoY

	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Enterprise revenue (INR mn)	4,333	4,941	4,235	4,234	5,496	5,810	4,980	4,670	6,360
From owned hotels	2,713	3,103	2,555	2,718	3,374	3,630	3,000	2,930	3,720
From managed and franchised hotels	1,620	1,838	1,680	1,516	2,122	2,180	1,980	1,740	2,640

Source: Company, Elara Securities Research

Exhibit 9: Proforma management fees for standalone LEMONTREE

Particulars (INR mn)	FY26E	FY27E	FY28E
Total management fees	1,980	2,318	2,597
Management fees from third party	803	1,083	1,279
Management fees from Fleur	1,177	1,236	1,319


Source: Elara Securities Estimate

Exhibit 10: Fleur Hotels – Indicative proforma

Particulars (INR mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E
Revenue	8,100	9,910	11,890	13,077	13,730	14,653
YoY (%)		22.3	20.0	10.0	5.0	6.7
EBITDA	3,590	4,230	5,090	5,440	5,801	6,330
YoY (%)		17.8	20.3	6.9	6.6	9.1
EBITDA margins (%)	44.3	42.7	42.8	41.6	42.3	43.2

Source: Company, Elara Securities Estimate

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
08-Aug-2023	Buy	114	95
13-Nov-2023	Accumulate	121	114
08-Feb-2024	Accumulate	154	138
03-Jun-2024	Accumulate	160	140
08-Aug-2024	Buy	160	126
18-Nov-2024	Buy	152	122
11-Feb-2025	Buy	185	146
14-Jan-2026	Accumulate	157	149

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "**Foreign Counterparty**"). Avior Capital Markets US LLC ("**Avior US**"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "**Exchange Act**") may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("**FINRA**") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/> and Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("**Foreign Counterparty**") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("**Avior UK**"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("**Report**") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India
Elara Securities (India) Private Limited
 One International Center, Tower 3,
 21st Floor, Senapati Bapat Marg,
 Elphinstone Road (West)
 Mumbai – 400 013, India
 Tel : +91 22 6164 8500

Europe
Elara Capital Plc.
 6th Floor, The Grove,
 248A Marylebone Road,
 London, NW1 6JZ,
 United Kingdom
 Tel : +44 20 7486 9733

USA
Elara Securities Inc.
 230 Park Avenue, Suite 2415,
 New York, NY 10169, USA
 Tel: +1 212 430 5870
 Fax: +1 212 208 2501

Asia / Pacific
Elara Capital (Asia) Pte.Ltd.
 One Marina Boulevard,
 Level 20,
 Singapore 018989
 Tel : +65 6978 4047



**Managing
Director**

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of
Research**

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &
Australia**

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate
Access,
Conference &
Events**

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#)

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
 Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
 Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509